2nd Quarter - Report — THE MICHAEL J. FOX FOUNDATION FOR PARKI… for THE MICHAEL J. FOX FOUNDATION FOR PARKI… (2021)

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm

THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH

Client

THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH

Income

—

Expenses

$27,000

Expense method

A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing	Filed	Amount	Counted
2nd Quarter - Report (this page)	Jul 19, 2021	$27,000	Replaced
2nd Quarter - Amendment	Aug 3, 2021	$72,000	Yes

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

General Parkinson's disease information about symptoms, causes, health coverage, and health costs Advocating for Parkinson's patients during Covid-19 S.253 the Cannabidiol and Marihuana Research Expansion Act S.1467/H.R.2916 the VA Medicinal Cannabis Research Act S.1670/H.R.3321 the Credit for Caring Act S.464/H.R.2163 Safe Step Act H.R.3013 COVID Vaccine Transportation Access Act

Lobbyist	Covered position, as disclosed
AARON POLACEK New	Public Policy Officer

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Environmental Protection Agency (EPA); Natl Institutes of Health (NIH); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS)

Bills named: S. 464 (117th), H.R. 3321 (117th), S. 1670 (117th), H.R. 2916 (117th), H.R. 3013 (117th), S. 1467 (117th), H.R. 2163 (117th), S. 253 (117th)

Medicare/Medicaid MMM

Telehealth flexibilities and making current telehealth rules permanent Medicare Part D design and benefits, drug pricing principle S.464/H.R.2163, the Safe Step Act of 2021 S.828/H.R.432, the Mental Health Access Improvement Act H.R.2080, the Seniors Access to Vaccine Ensured Act H.R.3173 Improving Seniors Timely Access to Care S.2061 the Telemental Health Care Access Act

Lobbyist	Covered position, as disclosed
AARON POLACEK	Associate Director, Public Policy
DUSTIN WATSON New	Director, Government Relations & Public Policy

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); SENATE; Environmental Protection Agency (EPA)

Bills named: H.R. 2080 (117th), H.R. 2163 (117th), S. 464 (117th), S. 2061 (117th), H.R. 432 (117th), S. 828 (117th), H.R. 3173 (117th)

Veterans VET

General education regarding impacts of the Department of Defense's medical research programs and impact on veterans. Inclusion of PD and PD-related diseases as presumptive conditions when veterans are exposed to associated toxins.

Lobbyist	Covered position, as disclosed
BRITTANY MEYER	Senior Associate Director, Public Policy
AARON POLACEK	Associate Director, Public Policy

Contacted: Health & Human Services, Dept of (HHS); Environmental Protection Agency (EPA); Natl Institutes of Health (NIH); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS)

Budget/Appropriations BUD

Funding for the 2022 Appropriations bill including requests for: Department of Defense National Institutes of Health Centers for Disease Control and Prevention Food and Drug Administration

Lobbyist	Covered position, as disclosed
BRITTANY MEYER	Senior Associate Director, Public Policy
DUSTIN WATSON New	Director, Government Relations & Public Policy

Contacted: Natl Institutes of Health (NIH); Food & Drug Administration (FDA); Environmental Protection Agency (EPA); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Agriculture AGR

General education on chemicals that trigger Parkinson's disease, including TCE, paraquat, and others.

Lobbyist	Covered position, as disclosed
BRITTANY MEYER	Senior Associate Director, Public Policy
DUSTIN WATSON New	Director, Public Policy

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Environmental Protection Agency (EPA); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS)

Environment/Superfund ENV

Education around environmental causes of neurological disease and support for more research.

Lobbyist	Covered position, as disclosed
BRITTANY MEYER	Senior Associate Director, Public Policy

Contacted: Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); Environmental Protection Agency (EPA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

Pharmacy PHA

General education around pharmaceuticals related to Parkinson's disease

Lobbyist	Covered position, as disclosed
BRITTANY MEYER	Senior Associate Director, Public Policy

Contacted: Natl Institutes of Health (NIH); SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Environmental Protection Agency (EPA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.